Comparing PainReform (NASDAQ:PRFX) and TG Therapeutics (NASDAQ:TGTX)

TG Therapeutics (NASDAQ:TGTX) and PainReform (NASDAQ:PRFX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Profitability

This table compares TG Therapeutics and PainReform’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	14.24%	33.79%	14.02%
PainReform	N/A	N/A	N/A

Institutional and Insider Ownership

58.6% of TG Therapeutics shares are held by institutional investors. Comparatively, 37.3% of PainReform shares are held by institutional investors. 9.2% of TG Therapeutics shares are held by insiders. Comparatively, 34.4% of PainReform shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares TG Therapeutics and PainReform’s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$233.66 million	10.92	$12.67 million	$0.23	71.78
PainReform	N/A	N/A	-$9.34 million	N/A	N/A

TG Therapeutics has higher revenue and earnings than PainReform.

Risk and Volatility

TG Therapeutics has a beta of 2.33, meaning that its share price is 133% more volatile than the S&P 500. Comparatively, PainReform has a beta of 0.73, meaning that its share price is 27% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for TG Therapeutics and PainReform, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	0	1	5	0	2.83
PainReform	0	0	0	0	N/A

TG Therapeutics presently has a consensus price target of $29.83, suggesting a potential upside of 80.70%. Given TG Therapeutics’ higher possible upside, analysts plainly believe TG Therapeutics is more favorable than PainReform.

Summary

TG Therapeutics beats PainReform on 9 of the 10 factors compared between the two stocks.

About TG Therapeutics

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

About PainReform

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.